The Max Foundation Renews and Expands Agreement with Incyte
The Max Foundation is proud to announce it has signed a renewed collaboration agreement with Incyte – a dedicated pharmaceutical partner and member of our humanitarian pact.
Since February 2017, Incyte has partnered with The Max Foundation to assist patients with cancer in Central Asia and Eastern Europe who are in need and unable to access treatment. The renewal by Incyte will allow The Max Foundation, through our drug donation program Max Access Solutions, to expand the number of patients who may be eligible to receive treatment with Iclusig (ponatinib) from 35 to up to 50 at no cost for as long as needed.
“As we work to expand treatment access for patients in low-income countries, we are grateful to have committed partners like Incyte,” said Pat Garcia-Gonzalez, CEO and co-founder of The Max Foundation. “We’re so excited to not only continue our collaboration, but also to expand its size and bring effective medicine to more patients in need.”
“At Incyte we are fully aligned with the mission of The Max Foundation, focused on increasing patient access to care, support, and treatment,” added Jonathan Dickinson, General Manager of Incyte in Europe. “We are proud to be part of a program dedicated to making cancer treatments available to appropriate patients in Central Asia and Eastern Europe. We are happy and privileged to partner with and support to The Max Foundation’s efforts and look forward to another year of making a difference for patients with cancer.”
We at The Max Foundation express our thanks to Incyte for their continued collaboration, and will keep an ear out for the Incyte Bell (pictured below, and rung once each week for each new patient treated).
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
Spot On CML: Improving CML Diagnostics One Patient at a Time
February 21, 2018 · The Max Foundation and Dr. Jerry Radich of the Fred Hutchinson Cancer Research Center are partnering to help tackle the problem of access to accurate tests for chronic myeloid leukemia (CML) diagnostics in low- and middle-income countries through Spot On CML. Spot On CML is a low-cost, paper-based diagnostic testing method for CML, developed by Dr. Radich’s lab at Fred Hutch. Through a Spot On CML test, a physician spots a patient’s blood onto a paper test card and sends it to Dr. Radich’s lab for processing, where they perform accurate diagnostic testing on the samples even after weeks of transport. Once patients are diagnosed, The Max Foundation connects them with available treatments free of charge.
The Critical Role of Humanitarian Donations
In a recent commentary published in the Journal of Global Oncology, co-authors Pat Garcia-Gonzalez MA, Gilberto Lopes MD, Erin Schwartz and Lawrence Shulman MD, clearly outline the need and efficacy of humanitarian donation programs using lessons learned from the success of joint access initiatives between Novartis and The Max Foundation.
The Max Foundation expands collaboration with Pfizer
The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer’s innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.
The Max Foundation uses cookies to improve your experience on our site. Please read our Privacy Policy for more information.
